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Summary. A long-standing goal in cancer research is to 
identify cellular functions that have selective roles in 
regulating neoplastic pathophysiology. Farnesyl- 
transferase inhibitors (FTIs) are a novel class of cancer 
chemotherapeutics which have little effect on normal 
cell physiology but which inhibit or reverse malignant 
cell phenotypes. FTIs were originally developed as a 
strategy to inhibit oncogenic Ras, the activity of which 
depends upon posttranslational farnesylation. However, 
recent work indicates the antineoplastic effects of FTIs 
are not linked to Ras inhibition but instead to alteration 
of RhoB, a small GTPase of the Rho family of 
cytoskeletal regulators that controls trafficking of cell 
surface receptors. Rho proteins integrate signals from 
integrins and cytokine receptors with cell shape via the 
actin cytoskeleton. A connection between FTIs and Rho 
alteration is  interesting given that histological 
differences have long been used to define clinical cancer. 
RhoB is dispensable for normal cell  growth and 
differentiation in mice. Thus, research into the 
antineoplastic effects of FTIs has led to the identification 
of a function(s) that is unnecessary for normal cell 
physiology but crucial for controlling malignant 
phenotypes. 
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Pharmacological inhibitors of the housekeeping 
enzyme farnesyltransferase (FTIs) inhibit malignant 
growth in a wide variety of murine models and human 
tumor cell lines. In contrast, FTIs have little effect on 
normal cell proliferation, viability, or differentiation. The 
different responses of normal and malignant cells are 
interesting because they suggest that FTIs identify a 
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unique feature of neoplastic pathophysiology. Notably, 
while it has become apparent that FTIs can interfere 
specifically with malignant growth, it also has become 
apparent that they do not have to inhibit isoprenylation 
of Ras to do so. The evidence that the antineoplastic 
effects of FTIs can be unlinked from Ras and instead 
linked to Rho is suweyed here. A Rho-based model can 
explain why FTIs produce such diverse biological 
responses in different cell and animal models and 
suggests new ways to apply and interpret the effects of 
FTIs in the oncology clinic. Possible connections that 
are emerging between Rho function and the actions and 
histopathology of cancer cells are also covered in this 
review. On the basis of recent advances we propose that 
Rho effector signaling molecules may be useful targets 
for cancer drug development. 
Farnesyltransferase inhibitors selectively target 
cancer cell phenotypes 
The development of FTIs was based on the need of 
oncogenic Ras for posttranslational farnesylation 
(reviewed in Gibbs et al., 1994; Oliff, 1999). This 
founding discovery initiated the area of protein 
isoprenylation research and led to the identification of 
three protein-isoprenyl transferases in cells, farnesyl 
transferase (FT), geranylgeranyl transferase type 1 (GGT- 
1), and geranylgeranyl transferase type 11 (GGT-11). Each 
of these housekeeping enzymes catalyze the transfer of 
farnesyl (C15) or geranylgeranyl (C20) isoprenoids from 
farnesyl or geranylgeranyl pyrophosphate to cysteine 
thiol groups in the C-termini of protein substrates. FT 
and GGT-1 share a subunit and similar mechanism of 
action whereas the action of GGT-11 is mechanistically 
different (Casey and Seabra, 1996; Zhang and Casey, 
1996). Small GTPases of the Ras superfamily represent a 
major fraction of isoprenylated proteins in the cell 
(-0.5% of the proteome). In general, FT and GGT-1 
modify Ras and Rho proteins whereas GGT-11 modifies 
Rab proteins. Since al1 mutant Ras proteins involved in 
human cancer are modified exclusively by FT, 
compounds that specifically inhibit FT were sought as a 
strategy to block the activity of oncogenic Ras in cancer 
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cells (Gibbs and Oliff, 1997; Oliff, 1999). Most 
isoprenylated proteins are geranylgeranylated. Also, 
while there is some overlap in the protein substrate 
specificities between FT and GGT-1, in cells FT is solely 
responsible for the transfer of farnesyl isoprenoid and 
GGT-1 is solely responsible for the transfer of 
geranylgeranyl isoprenoid. Thus, 'pure' FTis affect only 
the relatively fewer number of farnesylated proteins in 
cells. Interestingly, some FT substrates are geranyl- 
geranylated by GGT-1 if FT activity is abolished (see 
below). This effect of FTI treatment, which leads to an 
increase in overall protein geranylgeranylation in cells, 
turns out to be important to the mechanism through 
which FTIs inhibit malignant cell growth, as described 
below. 
In H-Ras transformation models, FTIs inhibit 
modification of newly synthesized H-Ras protein and 
suppress anchorage-independent cell growth. Loss of 
anchorage-independence correlates with reversion to a 
flat cell phenotype which is permissive for proliferation 
under anchorage-dependent conditions, with division 
rates similar to normal cells (James et al., 1993; 
Prendergast et d., 1994). Notably, little if any toxicity is 
associated with phenotypic reversion and loss of 
anchorage-independence under standard in vitro culture 
conditions. Cells transformed by K-Ras and N-Ras are 
also susceptible to growth suppression by FTis (although 
less so than H-Ras-transformed cells), as are many 
human tumor cell lines that harbor activated K-Ras 
(Sepp-Lorenzino et al., 1995). Similarly, FTIs block 
malignancy in a variety of xenograft and transgenic 
mouse models, where FTIs either impede tumor growth 
or elicit tumor regression, respectively (Kohl et al., 1994, 
1995; Nagasu et al., 1995; Barrington et al., 1998; Liu et 
al., 1998; Mangues et al., 1998; Norgaard et al., 1999). 
Significantly, regressions in transgenic animals are not 
confined to H-Ras models but can also be seen in models 
where tumorigenesis is driven by N-Ras or K-Ras 
(Mangues et al., 1998; C. Omer, pers. comm.). 
Regressions are associated with ceil cycle inhibition but 
also with increased apoptosis (Barrington et al., 1998; 
Norgaard et al., 1999). This is notable because most 
FTIs do not induce apoptosis of Ras-transformed cells in 
vitro unless cells are deprived of either substratum or 
cytokines (Lebowitz et al., 1997b; Suzuki et d., 1998), 
events which lead to loss of PI3'K-AKT signals that are 
crucial for survival of FTI-treated cells (Du et al., 
1999~). Significantly, normal cells are not susceptible to 
FTi-induced apoptosis under the same conditions which 
lead to killing of Ras-transformed cells, highlighting a 
difference in survivai requirements between normal and 
Ras-transformed cells (Du et al., 1999~). Based on the 
fact that AKT status can influence FTI response in 
certain setting, 1 have suggested that differences in AKT 
activity might explain the differences in FTI response 
seen in xenograft and transgenic models, where cytokine 
and adhesive environments likely differ (see below). In 
any case, in support of clinical utility the survival 
mechanism disrupted by FTIs appears to be largely p53- 
independent (Lebowitz et al., 1997%; Barrington et al., 
1998; Du et al., 1 9 9 9 ~ ) .  In summary, FTIs exhibit 
antiproliferative and proapoptotic effects that are quite 
selective for malignant cells. 
Ras alteration is not crucial to the antineoplastic 
effects of FTls 
Although not widely appreciated, a close 
examination of the FTI literature reveals that the 
antineoplastic effects of FZls can in many instances be 
separated from their effects on Ras farnesylation (Cox 
and Der, 1997; Lebowitz and Prendergast, 1998b). The 
first indication was that the kinetics of FTI-induced 
phenotypic reversion were simply too rapid to be 
accounted for by depletion of processed H-Ras from 
cells (Prendergast et al., 1994). Fully modified H-Ras is 
long-lived, with a haif-life of 24 hours (Ulsh and Shih, 
1984). FTIs block modification of modified Ras, not its 
steady-state leve1 or activity once modified, so 2-3 days 
of drug treatment is needed to deplete it from cells. 
However, reversion of H-Ras transformation is achieved 
within 18 to 24 hours of drug treatment, when modified 
Ras levels persist at 50% their pretreatment level. 
Furthermore, once initiated by a single dose of drug, the 
reverted phenotype persists for days after IT activity and 
fully modified Ras returns to pretreatment levels 
(Prendergast et al., 1994). This interesting long-lived 
phenotype, which resembles a pseudo-differentiation 
state in its stability, has been traced to the ability of FTIs 
to upregulate collagen Ia2 period. This stable growth 
inhibitory collagen isofonn must be suppressed by Ras 
for it transform cells (Travers et al., 1996; Andreu et al., 
1998) and that FTIs must derepress to elicit and maintain 
the reverted phenotype (Du et al., 1999b). Consistent 
with a Ras-independent effect, the kinetics of this gene 
induction parailels phenotypic reversion, occurring by 16 
hr after drug treatment. The ability of lTIs to induce a 
long-lived reversion through upregulation of long-lived 
growth inhibitory protein(s) may have clinical benefit. In 
any case, neither initiation nor maintenance of reversion 
to a benign phenotype is correlated with significant 
steady-state depletion of farnesylated Ras protein. 
There is other evidence that Ras alteration can be 
uncoupled from biological response. First, rodent 
fibroblasts transformed with N-myristoylated Ras remain 
susceptible to FTI-induced reversion and suppression of 
anchorage-independent growth, even though the activity 
of N-myristoylated Ras is independent of farnesylation 
(Cox et al., 1994; Lebowitz et al., 1995). Second, while 
approximately 70% of human tumor cell lines are 
susceptible to growth inhibition by FTIs, there is no 
correlation with Ras mutation (Nagasu et al., 1995; 
Sepp-Lorenzino et al., 1995). Lastly, FTIs can inhibit 
malignant growth induced by activated K-Ras or N-Ras, 
but they do not inhibit isoprenylation of these proteins. 
This unexpected result, which have raised concerns 
among some investigators whether FTIs will be useful 
anti-cancer drugs, is explained by the observation that 
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GGT-1 can geranylgeranylate K-Ras and N-Ras in the 
absence of FT activity (Sepp-Lorenzino et al., 1995; 
Lerner et al., 1997; Whyte et al., 1997; Mangues et al., 
1998; Servais et al., 1998). This "GGT-1 shunt pathway" 
allows oncogenic K-Ras and N-Ras to remain membrane 
bound and active in FTI-treated cells. Notably, as 
mentioned above, FTIs still inhibit malignant growth 
induced by K-Ras or N-Ras. This fact suggests that iTIs  
may exhibit anti-cancer activity through Ras- 
independent mechanisms. 
The antineoplastic effects of FTls can be explained 
by alteration of RhoB 
1 first noticed that FTIs affected actin stress fibers in 
normal cells in 1992. Since the kinetics of biological 
response and H-Ras depletion in the fibroblast model 
under study did not fit, 1 hypothesized that alteration of a 
farnesylated Rho protein may be crucial to the 
mechanism through which FTIs inhibit malignant cell 
growth (Prendergast et al., 1994). Subsequent studies 
focused on RhoB as a paradigm for testing this 
hypothesis, which was corroborated by severa1 lines of 
evidence. RhoB is a member of the Rho family that is 
-90% similar to RhoA, but which unlike RhoA is 
located on early endosomes and to a lesser extent on the 
nuclear membrane and periphery (Adamson et al., 1992; 
Lebowitz et al., 1995; Zalcman et al., 1995; Lebowitz 
and Prendergast, 1998a). Consistent with an endosomal 
location, RhoB functions in trafficking of the EGF 
receptor through a mechanism that requires recruitment 
of the Rho effector kinase PRKIPKN to endosomes 
(Mellor et al., 1998; Gample et al., 1999). The role of 
RhoB in recruiting the PRKIPKN kinase(s) to 
endosomal membranes is analogous to the role of Ras in 
recruiting the Raf kinase to plasma membrane. Unlike 
most small GTPases proteins, RhoB is short-lived 
(Lebowitz et al., 1995). Therefore, farnesylated RhoB is 
depleted rapidly from cells by FTI treatment. One 
unusual feature of RhoB is that it exists in both 
farnesylated or geranylgeranylated forms in the cell, in 
approximately equal populations, for reasons that are 
unknown. 
RhoB has severa1 features arguing it is a crucial FTI 
target (Lebowitz and Prendergast, 1998b). First, FTI 
treatment inhibits farnesylation of RhoB and leads to an 
elevation of geranylgeranylated RhoB, due to the 'shunt 
pathway' for isoprenylation provided by GGT-1. These 
events correlate with a change in intracellular 
localization and loss of the growth-stimulatory activity 
of RhoB (Lebowitz et al., 1995, 1997a). Thus, although 
RhoB remains isoprenylated, it is depleted from its 
normal localization in the cell and likely suffers loss-of- 
function as a result. Second, Rho is crucial for Ras 
transformation: dominant inhibitory mutants of RhoB 
suppress transformation by H-Ras (Prendergast et al. 
1995). Third, ectopic expression of N-myristoylated 
RhoB makes Ras-transformed cells resistant to FTIs 
(Lebowitz et al., 1995; Prendergast et al., 1995). This 
observation argues that loss of farnesylated RhoB is part 
of the mechanism at some level. Lastly, the elevation of 
geranylgeranylated RhoB (RhoB-GG) elicited by FTI 
treatment is sufficient on its own to cause phenotypic 
reversion and growth inhibition (Du et al., 1999a). Since 
RhoB-GG appears to be mislocalized in cells, for 
reasons that are unclear, we have hypothesized that 
RhoB-GG in FTI-treated cells may sequester effectors 
such as  PRKIPKN away from sites of action on 
endosomal membranes. Recent work has established that 
RhoB-GG is necessary, as  well as  sufficient, for 
apoptotic and antineoplastics effects of FI'Is (Liu et al., 
2000). 
It should be emphasized that the growth inhibitory 
effects of RhoB-GG are not confined to 'morphologica17 
contexts and are not specific to rodent fibroblast models: 
RhoB-GG also selectively inhibits the growth of FTI- 
susceptible human carcinoma cells (Du and Prendergast, 
1999). Thus, there is a good correlation between the 
susceptibility to growth inhibition by FTIs and RhoB- 
GG. Moreover, RhoB alteration is germane to human 
epithelial cancer cells, where phenotypic effects may or 
may not be apparent. Taken together, these studies 
establish that the antineoplastic properties of FI'Is can be 
traced to alteration of RhoB, and they identify a gain of 
function aspect of the mechanism involving production 
of a potentially dominant inhibitory RhoB-GG. 
lmplications of a Rho-based mechanism for FTI 
action 
One old question is why FTIs should not affect the 
proliferation and differentiation of normal cells in vitro 
and in vivo, since Ras is necessary for these processes. 
This issue may be partly addressed by the action of a 
GGT-1-mediated 'shunt pathway', which could lead to 
alternate isoprenylation and maintenance of the function 
of K-Ras and possibly other FT substrates. However, it is 
notable that mice that have homozygous deletions of 
rhoB develop without any apparent defect and are fertile 
(S. Liu and T. Jessell, unpublished observations). Thus, 
loss of RhoB does not have consequences for normal cell 
growth or differentiation, mirroring the lack of any 
discernable effect of FTI treatment in normal mice. It is 
also notable that while elevated levels of RhoB-GG can 
inhibit the growth of FTI-susceptible malignant cells, 
this same event does not affect the growth of normal 
cells (Du et al., 1999a; Du and Prendergast, 1999). In 
summary, a RhoB-based mechanism for FTI action is 
consistent with the lack of FTI effects on normal cells. 
A second question concerns why malignantly 
transformed cells respond s o  differently to drug 
treatment in various preclinical assays. For example, 
cytostatic responses predominate in xenograft models 
but cytotoxic responses can be seen transgenic models. 
The known connections between Rho function and 
integrin-dependent adhesion signaling offers a new 
vantage point to address this question. Environmental 
influences mediated by adhesion might be expected to 
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determine how cells respond to FTIs if the drugs work 
by altering a Rho signal(s). In support of this view, our 
laboratory has shown that the response of H-Ras- 
transformed Ratl cells to FH treatment in vitro can be 
dramatically altered simply by varying substratum 
adhesion parameters. In tissue culture dishes, cells revert 
but continue to proliferate in an anchorage-dependent 
manner. In soft agar, where neither focal adhesions nor a 
tensile actin cytoskeleton can be organized, but where 
integrin-ligand interactions can persist (due to the 
deposition of ECM by cells in the agar media), cells 
slow or arrest division but remain viable. Lastly, when 
placed in frank suspension, which completely deprives 
integrin-ligand interactions, cells undergo apoptosis 
(Kohl et al., 1993, 1994; Prendergast et al., 1994; 
Lebowitz et al., 1995, 1997b). Importantly, al1 these 
responses to FTIs are abolished by ectopic expression of 
N-myristoylated RhoB (Lebowitz et al., 1995, 1997b). 
Thus, one can establish a link between RhoB alteration 
and the effects of FTIs in different adhesive 
environments. 
We have suggested that the role of adhesive cues in 
determining response rnay also address why malignant 
cells can not totally destroyed in FTI-treated H-Ras 
transgenic mice. In this model, tumors can be completely 
regressed from a histological standpoint. However, latent 
cells apparently persist in a 'reverted' state, because even 
after long periods of drug treatment removal from the 
treatment protocol leads to rapid recurrence of the tumor 
(Kohl et al., 1995). We suggest that in the periphery of 
the tumor, where normal adhesion cues rnay be available 
(e.g. basement membrane), cells rnay revert to a benign 
phenotype upon drug exposure such that they could 
survive and persist. The flat phenotype seen in vitro rnay 
occur also in vivo such that the 'reverted' but malignant 
cell could not be identified histologically at this point. In 
contrast, cells without access to normal 
adhesion cues would engage an anoikis program 
and die. Upon drug removal, malignant cells in the 
'reverted' and benign state would re-revert, as seen 
in vitro, allowing the tumor to rapidly re-emerge as 
observed. 
A role for RhoB-GG in the FTI mechanism 
addresses an apparent conundrum of the model: if FTis 
act by blocking Rho function why should they stimulate 
stress fiber formation, since this would be expected to 
require Rho activity? In its structure and localization in 
FTI-treated cells, RhoB-GG partly mimics RhoA. Thus, 
in FTI-treated cells RhoB-GG rnay mimic some 
functions of RhoA, including its ability to induce stress 
fibers. One can not rule out the possibility that the stress 
fiber-inducing activity of FTIs is due to loss of function 
in a different farnesylated Rho protein that opposes the 
activity of RhoA. However, in support of the first 
interpretation, ectopic expression of RhoB-GG increases 
actin stress fiber formation in a manner similar to FTI 
treatment. In summary, Rho-GG rnay have both 
dominant positive and dominant inhibitory functions in 
cells. 
Cancer cell histopathology and Rho function: 
correlation or causation? 
For many years, cancer has been defined by 
histological criteria and by the propensity of malignant 
cells to move around the body inappropriately. Given 
these links, one might expect that Rho proteins would be 
important in cancer, because of their roles in controlling 
cell shape and adhesion and because altered adhesive 
properties are a hallmark of the malignant cell. Evidence 
and argument can be drawn in support of a causal 
connection between Rho function and cancer. Rho 
proteins seem likely to mediate environmental cues that 
determine where tumor cells go and what they can do, 
including responses to chemotherapeutics which are in 
many cases controlled by the particular tissue site of 
tumor deposition (Killion et al., 1999). Notably, Rho 
proteins are elevated strongly in cancer cells, including 
RhoA (Fritz et al., 1999). Cornmercially available RhoB 
antibodies known to us do not discriminate very well 
between the closely-related RhoA and RhoB proteins, so 
immunohistological experiments using RhoB antibodies 
need to be controlled carefully. Perhaps the most direct 
causal link is suggested by evidence that the Rho 
effector ROCK kinase is important for invasion (Itoh et 
al., 1999). We hypothesize that RhoB-GG rnay 
dominantly inhibit RhoA and other Rho functions based 
on elevations and mislocalization of RhoB-GG in FTI- 
treated cells. Lastly, the RhoB effector kinase PRWPKN 
has been reported to bind to and alter the substrate 
specificity of the AKT regulatory kinase PDKl 
(Balendran et al., 1999). This observation suggests there 
rnay be crosstalk between RhoB-dependent and AKT- 
dependent survival signals that rnay be important in 
malignantly transformed cells. rhoB-1- cells under study 
in our laboratory exhibit alterations in motility, integrin 
modification, and focal adhesion formation, supporting a 
role for RhoB in these processes (A. Liu and G.C.P., 
unpublished observations). In summary, we anticipate 
that continued investigations of Rho functions in cancer 
cells will provide additional support for the notion that 
there is a causative rather than correlative relationship 
between Rho activity and the histology and 
pathophysiology of cancer. 
FTls in the clinic 
Data from human trials presented at recent oncology 
meetings by severa1 pharmaceutical companies suggest 
that systemic exposure produces only limited toxicities 
(e.g. neutropenia), even at high doses, and that it is quite 
possible to achieve serum concentrations which are 
sufficient to effectively inhibit FT activity. The former 
results are consistent with the lack of toxicity to normal 
cells in preclinical models. However, while cancer 
preclinical models do a fair job of predicting toxicity 
they do poorly at predicting efficacy. Phase 11 trials will 
ultimately address this question. It rnay require patience 
and persistence to learn how to obtain efficacy in 
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humans, since mechanistic studies from preclinical 
models suggest that the cytotoxic activity of FTIs can be 
inhibited in many ways. Resistance to FTIs can be 
selected readily in vitro by a variety of MDR- 
independent mechanisms (Kohl et al., 1995; Prendergast 
et al., 1996), including by mutation of FT in ways that 
lead to reduced FTI affinity (Del Villar et al., 1999). 
Dmg responses rnay be shifted also by overexpression of 
FT itself, an event which has been shown to be sufEicient 
on its own to transform murine 3T3 fibroblasts (Nagase 
et al., 1999). In addition, Bcl-XL overexpression can 
block FTI-induced apoptosis, offering another posible 
mechanism to achieve cytotoxic resistance (Prendergast 
et al., 1996; Lebowitz et al., 1997b). Other mechanisms 
of resistance are involved because Bcl-XL- 
overexpressing cells remain susceptible to growth 
inhibition by FTIs (Lebowitz et al., 1997b). Lastly, AKT 
activation can block both the proapoptotic and 
antitransforming effects of FTIs in cells (Du et al., 
1999~).  The proapoptotic Bcl-2 family member Bad can 
be phosphorylated by AKT and then proceed to bind to 
and inhibit Bcl-XL activity. Therefore, there rnay exist a 
common linear pathway involving PI3'K-AKT-BAD- 
BCL-XL signals which can elicit FTI resistance. While 
further investigations are needed in this area, the 
preclinical data predict that FTIs rnay have lesser 
efficacy against tumors that have activated AKT (e.g. 
due to PTEN mutation) or that overexpress antiapoptotic 
Bcl-2 family proteins. Therefore, knowing the status of 
these genes in patients under study rnay help one 
interpret clinical data. 
Efficacy rnay be improved by combinatorial 
application with other modalities that promote apoptosis. 
For example, since PI3'K-AKT activation can mask the 
proapoptotic effects of FTIs (Du et al., 1 9 9 9 ~ ) ~  inhibiting 
the PI3'K-AKT pathway rnay be valuable. One way this 
might be achieved is to combine FTIs plus PI3'K 
inhibitors, which exist currently. As noted above, this 
combination does not interfere with the viability of 
normal cells even though it leads to a loss of viability of 
Ras-transformed cells (Du et al., 1 9 9 9 ~ ) .  Similarly, 
combinations with classical chemotherapeutics or 
radiotherapy rnay be useful. FTIs can sensitize the 
response of human tumor cell lines when added in 
combination with cisplatin, taxanes, or gemcitabine 
(Moasser et al., 1998; Sun et al., 1999). Similarly, FTIs 
can sensitize transformed rodent cells and human tumor 
cell lines to gamma irradiation (Bernhard et al., 1996, 
1998; Cohen-Jonathan et al., 1999). Ras has been 
suggested to be a key target in these settings but RhoB 
rnay actually be germane. RhoB expression is elevated 
by DNA damage and other stresses (Fritz et al., 1995; 
Fritz and Kaina, 1997). Moreover, when transformed by 
oncogenes, rhoB-1- cells exhibit differences in the 
cytotoxic response to gamma irradiation or DNA 
damaging drugs (A. Liu and G.C.P., unpublished 
obse~ations).  Thus, the ability of FTIs to sensitize cells 
to radiotherapy or traditional chemo-therapeutics rnay 
also be linked to altering Rho-dependent processes. In 
closing, preclinical data argue that FTIs rnay be valuable 
as chemosensitizers or radiosensitizers even if they have 
limited escacy  as primary therapeutics. 
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